NCIt definition : A neutralizing human monoclonal antibody isolated from convalescent patients with
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed
against the spike (S) protein, that can potentially be used for passive immunization
against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically
targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and
entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression
of the disease and accelerate recovery, and may potentially provide temporary protection
against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2,
plays an essential role in the infection pathway of the SARS-CoV-2 virus.;
UNII : F0LZ415Z3B;
CAS number : 2420564-02-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2420564-02-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;